Evidence map›Paper›PMID 20087628›Full record

Trial reportInflammation research : official journal of the European Histamine Research Society ... [et al.]2010

Plasma histamine levels (H) during adjunctive H1-receptor antagonist treatment with loratadine in patients with active inflammatory bowel disease (IBD).

M Raithel, A Nägel, Y Zopf, Th deRossi, Ch Stengel, A Hagel, J Kressel, E G Hahn, P Konturek

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Use of Antihistamine Drugs in Colitis: A Review.Pharmaceuticals (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Histamine: an undercover agent in multiple rare diseases?Journal of cellular and molecular medicine · 2012
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

M RaithelFunctional Tissue Diagnostics, Department Medicine I, University Erlangen, Erlangen, Germany. martin.raithel@uk-erlangen.de
A Nägel
Y Zopf
Th deRossi
Ch Stengel
A Hagel
J Kressel
E G Hahn
P Konturek
Universitätsklinikum Erlangen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalColitis, UlcerativeCrohn DiseaseHistamineHistamine H1 AntagonistsHumansInflammatory Bowel DiseasesLoratadineMesalaminePrednisoloneAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalHistamineHistamine H1 AntagonistsLoratadineMesalaminePrednisolone

Identifiers

PMID20087628
OpenAlexW1976330657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.